Басты бетке

3 бет - Ең жақсы Әйелдерге арналған онкологиялық тексеру дәрігерлері - ЖОҒ-72 дәрігерлер

Контент Bookimed редакциялық саясатына сәйкес келеді және оның сапасын тексерген

Фахад Мавлюд

Yusuf Acikgoz

  • 4.9 Керемет 7 пікірлер
  • 10 жылдар тәжірибе
  • Түркия, Анқара, Lokman Hekim University Ankara Hospital
  • Associate Professor Dr. Yusuf AÇIKGÖZ
    Specialization: Medical Oncology

    Education:

    • 2004-2011: İnönü University Faculty of Medicine
    • 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
    • 2017-2022: Health Sciences University, Medical Oncology

    Professional Experience:

    • 2016-2017: Bingöl City Hospital, Internal Medicine
    • 2021-2022: Health Sciences University, Medical Oncology
    • 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
    • 2023-2024: Ohio State University, Medical Oncology
    • 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

    Clinical Trials, Courses, Certifications:

    Clinical Trials:

    • 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
    • 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

    Courses:

    • 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
    • 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
    • 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
    • 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
    • 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

    Certifications:

    • Ongoing: ECFMG Certification
    • 2024: CITI Responsible Conduct of Research (The Ohio State University)
    • 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
    • 2024: CITI Human Subjects Protection (The Ohio State University)
    • 2024: CITI Good Clinical Practice (The Ohio State University)
    • 2023: Occupational English Test (OET)
    • 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
    • 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
    • 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

    Memberships:

    • American Society of Clinical Oncology (ASCO) - 2022
    • Turkish Society of Medical Oncology - 2020
  • Толығырақ оқу
Өкпе рагын емдеу үшін операция
$10,940 - $16,410
Радиожиілікті абляция
$5,470 - $10,390
Да Винчи роботымен простатэктомия
$10,120 - $11,760
Ақпарат

Nail Paksoy

  • 4.5 Жақсы 2 пікірлер
  • 15 жылдар тәжірибе
  • аккредитациялар:
  • Түркия, Істанбұл, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Толығырақ оқу
Сүйекті резекциялау
$8,000 - $12,000
Жартылай қалқанша безді алып тастау
$3,500 - $4,500
Көмей рагында сәулелік терапия
$4,000 - $6,000
Ақпарат

Inta Jaunalksne

  • 5 Керемет 2 пікірлер
  • 49 жылдар тәжірибе
  • Латвия, Юрмала, Pallas Clinic
  • Dr. Inta Jaunalksne is an experienced immunologist with more than 30 years in the field. She specializes in virotherapy. She graduated from Riga Medical Institute and completed an internship in Internal Medicine. Dr. Jaunalksne is recognized as an expert in immunology.

    She leads the Clinical Immunology Center at Pauls Stradins Clinical University Hospital. Dr. Jaunalksne has played a key role in advancing virotherapy and immunological research. Her work has improved treatment results and introduced new therapies. She is well respected in clinical immunology.

  • Толығырақ оқу
Ақпарат

Rifaat Safadi

  • 4.4 Жақсы 12 пікірлер
  • 38 жылдар тәжірибе
  • Израиль, Іерусалім, Hadassah Medical Center
  • EDUCATION AND ADVANCED TRAINING COURSES

    • 1989 - received higher medical education at the Hebrew University;
    • 1995 - completed residency in internal medicine and gastroenterology at the Hadassah University Hospital.
    • 2001 - 2002 - Internship with Professor Scott Friedman in the Department of Liver Diseases at Sinai School of Medicine in New York.

    Today, Professor Rifaat Safadi is an outstanding specialist in the field of liver disease treatment, a member of the committee for the development of the somatic cell transplant center and the head of the liver disease unit at Hadassah Medical Center. The professor is a member of several international associations for the study of the liver and is the author of numerous articles in his specialty. Professor Safadi is a member of the editorial board of the scientific medical journal Clinical Science.

    Rifaat Safadi is a laureate of many scientific awards. In particular, he has been repeatedly awarded the Hadassah Prize for studying the process of immune modulation of liver fibrosis using mRNA. For achievements in the same field, the professor received the Sharon Donsky and the Israeli Association of Gastroenterology and Hepatology awards.

  • Толығырақ оқу
Ақпарат

Esra Bahadir Ulger

  • 5 Керемет 3 пікірлер
  • 21 жылдар тәжірибе
  • Түркия, Істанбұл, Medipol Acibadem District Hospital
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Ireri Asteinza

  • Жаңа
  • 35 жылдар тәжірибе
  • Мексика, Мехико, DR. IRERI ASTEINZA Clinic
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Edmundo Pichardo

  • Жаңа
  • 39 жылдар тәжірибе
  • Мексика, Мехико, DR. IRERI ASTEINZA Clinic
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Turkan Ozturk Topcu

  • Жаңа
  • 16 жылдар тәжірибе
  • Түркия, Істанбұл, Biruni University Hospital
  • Education

    Cumhuriyet University Faculty of Medicine, 2004
    Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
    Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015

    Experience

    MD Andeson Cancer Center, USA, 2008
    Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
    Moffit Cancer Center , USA 2022
    Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
    İdil State Hospital Internal Medicine Clinic, 2011
    Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
    Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
    Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
    Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

     

    Scientific Membership

    Turkish Medical Association (TTB)
    Turkish Society of Medical Oncology (TTOD)
    European Society for Medical Oncology (ESMO)
    American Society of Medical Oncology (ASCO)

     

    Medical Intrests

    • Breast Cancer
    • Lung Cancer
    • Colon Cancer
    • Stomach Cancer
    • Rectal Cancer
    • Ovarian Cancer
    • Liver Cancer
    • Oesophageal Cancer - Oesophageal Cancer
    • Kidney Cancer
    • Larynx Cancer - Cancer of the Larynx
    • Thyroid Cancer
    • Head and Neck Cancers
    • Gynaecological Cancers
    • Pancreatic Cancer
    • Oesophageal Cancer - Oesophageal Cancer
    • Uterine Cancer
    • Brain Cancers - Brain Tumours
    • Soft Tissue Cancer - Sarcomas
    • Prostate Cancer
    • Bladder Cancer
    • Bile Tract Cancer
    • Testicular Cancer
    • Cervical Cancer
    • Mouth, Tongue, Lip Cancers
    • Gastrointestinal System Cancers
    • Bone Tumours
    • Trachea and Bronchial Cancers
    • Skin Cancers - Skin Cancers
    • Skeletal System Tumours
    • Gallbladder Cancer
    • Mesothelioma
  • Толығырақ оқу
Томотерапия
$8,440 - $14,140
Брахитерапия
$10,000 - $12,000
Ақпарат

Senem Karabulut

  • Жаңа
  • 16 жылдар тәжірибе
  • Түркия, Істанбұл, Biruni University Hospital
  • Education

    Istanbul University Cerrahpaşa Faculty of Medicine, 2002
    Istanbul Fatih Sultan Mehmet Training and Research Hospital, Internal Medicine, 2010
    Istanbul University Oncology Institute (Çapa), Medical Oncology, 2015
    Medipol University Faculty of Medicine, Phytotherapy Education, 2018
    University of Health Sciences, Vocational School of Health, Molecular Oncology, PhD Program, PhD, 2023

    Experience

    University Hospital, Newark, New Jersey, USA, Observer (2003-2004)
    Siirt State Hospital, Internal Medicine (2010-2011)
    Siirt State Hospital, Medical Oncology (2015)
    Bakırköy Dr. Sadi Konuk Training and Research Hospital, Medical Oncology (2015-2018)
    Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Medical Oncology, (Professor Doctor) (2018-Present)
    Forensic Medicine 3. Specialization Board, Medical Oncology, Full Member (2019-Present)
    Liv Hospital, Ulus, Park-time, Medical Oncology (2020-2022)
    Şişli Kolan International Hospital, Park-time, Medical Oncology (2022-2023)

     

    Medical Intrests

    • Gastrointestinal System Tumours (Esophagus - Stomach and Large Bowel Cancer)
    • Hepatobiliary System Tumours (Liver-Biliary Tract and Pancreatic Cancer)
    • Breast Cancer
    • Lung Cancer
    • Genitourinary Cancers
    • Immunotherapies and Target Therapies
    • Molecular Oncology
    • Immunotherapies
    • Target Treatments
    •  

    Awards

    2010-YDUS (Subspecialty Examination) 14th place in Turkey
    2014- Oncology Institute Days Best Poster Award
    2015- Turkish Medical Oncology Society Board Exam Qualification
    2015- ESMO (European Society for Medical Oncology) Board Exam Qualification

  • Толығырақ оқу
Томотерапия
$8,440 - $14,140
Брахитерапия
$10,000 - $12,000
Ақпарат

Ismail Biri

  • Жаңа
  • 23 жылдар тәжірибе
  • Түркия, Анқара, Private Koru Ankara Hospital
  • Education

     

    İnönü Üniversitesi Tıp Fakültesi (ingilizce) 1995- 2002

     

    Work Experience

    Başbakanlık S.H.Ç.E.K. Genel Müdürlüğü Kurum Hekimliği (2003)

     

    Erciyes Üniversitesi Tıp Fakültesi Genel Cerrahi Uzmanlığı 2011

     

    Yüzüncü Yıl Üniversitesi Temel ve İleri Düzey Endoskopik Girişimler Eğitimi 2011

     

    İstanbul Hastanesi /Van 2011

     

    Özel Malatya Hastanesi / Malatya2012

     

    Bilgi Tıp Merkezi Keçiören /Ankara 2013

     

    Özel Koru Sincan Hastanesi Sincan/Ankara 2013

     

    Baş Tibb Mərkəzi /Baku Clinic Azerbaycan/Bakü 2013

     

    Yüksek İhtisas Üniversitesi Özel Koru Ankara Hastanesi 2019

     

    Özel Ankara Koru Hastanesi /Ankara 2019

    Medical Interests

    laparoscopic obesity
    Laparoscopic abdominal and inguinal hernia repairs (with the latest techniques)

    Postpartum laparascopic diastasis recti (the formation of a protrusion in the upper middle abdomen due to the separation of the muscles in the abdominal tissue) and abdominal hernias above the navel and and gobekustunde both diastasis recti repair and abdominal hernia repair from the skin with laparascopic scola method for the first time in Turkey laparascopic stomach hernia and antireflu surgery).  

    Laparoscopic gallbladder surgeries, including cleaning the bile duct with trans-cystic choledochal irrigation in patients with bile sludge and stones less than 5mm in the bile duct, performed in the same session

    Laparoscopic gallbladder surgeries in pregnant women during the 2nd and 3rd trimesters, i.e., after 12 weeks of pregnancy

    Laparoscopic Appendectomy in Pregnancy

    Anal disorders, anal fissures, all types of internal and external hemorrhoid surgeries, anal fissure, and anal fistula surgeries

    Thyroid surgeries and cancers, parathyroid surgeries and cancers

    Breast diseases and breast cancer surgery

    Oncological surgery; liver and gallbladder and bile duct surgeries, stomach cancer surgery, colon cancer surgery, and liver resections for metastatic liver tumors

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Elnur Sahibov

  • 4.4 Жақсы 32 пікірлер
  • 10 жылдар тәжірибе
  • Түркия, Істанбұл, Emsey Hospital
  • Dr. Elnur Sahibov is a licensed Radiation Oncologist with 8 years of medical training and clinical experience. He completed his undergraduate and specialization studies at Marmara University Faculty of Medicine. From 2012 to 2016, he focused on advanced radiation oncology techniques.

    Dr. Sahibov is known for his expertise in cancer treatment. He has helped improve patient outcomes and uses evidence-based protocols. He is accredited by leading medical institutions and is dedicated to ongoing professional development in oncology.

  • Толығырақ оқу
Тік ішекті резекциялау
$7,500 - $27,000
Ақпарат

Ernesto Segoviano

  • Жаңа
  • 19 жылдар тәжірибе
  • Мексика, Плайя-дель-Кармен, Ginecologo Playa del Carmen
Трахелэктомия
$3,000 - $3,500
Гистерэктомия (жатырды алып тастау)
$6,500 - $7,000
Ақпарат

Walter Querevalú

  • Жаңа
  • 36 жылдар тәжірибе
  • Мексика, Мехико, DR. IRERI ASTEINZA Clinic
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Ersin Ozturk

  • 5 Керемет 1 пікірлер
  • 28 жылдар тәжірибе
  • Түркия, Бұрса, Medicana Bursa Hospital
  • Dr. Ersin Öztürk, M.D., is a Professor of Medicine and an expert in General Surgery. His specialties include Surgical Oncology, Gastrointestinal and Laparoscopic Surgery, Obesity Surgery, Hernia Surgery, and Proctology. He holds a Ph.D. in Physiology. Dr. Öztürk completed his residency at Uludağ University and later conducted advanced research at the Cleveland Clinic Foundation in the USA.

    He is currently a Professor at Medicana Bursa Hospital. Dr. Öztürk has also served as Assistant and Associate Professor at Uludağ University and as Professor at KTO Karatay University. He is known for his important work in surgical innovation and medical education in Turkey.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Chaitainya Borde

  • Жаңа
  • 11 жылдар тәжірибе
  • Үндістан, Нашік, HCG Manavata Cancer Centre
  • Dr. Chaitainya Borde is a nuclear medicine specialist with 12 years of clinical experience. He is skilled in advanced nuclear scans, PET-CT imaging, and nuclear cardiology. He works in both diagnostic and therapeutic nuclear medicine.

    Dr. Borde has performed over 30,000 PET scans. He has managed more than 1,000 thyroid cancer patients. He is experienced in radioiodine and Lu-177 RN therapies. He has also published research papers in respected medical journals, showing his dedication to academic work.

  • Толығырақ оқу
Туыстық емес донордан алынған жұлың кемігін аллогендік трансплантациялау
$37,500 - $39,000
Уиппл операциясы
$8,000 - $10,000
Ақпарат

Shruti Kate

  • Жаңа
  • 15 жылдар тәжірибе
  • Үндістан, Нашік, HCG Manavata Cancer Centre
  • Dr. Shruti Kate is an experienced oncologist. She specializes in treating lung, breast, gynecological, and genitourinary cancers. She earned her MBBS from Lady Hardinge Medical College. She completed her MD in Internal Medicine at Maulana Azad Medical College. She also holds a DM in Medical Oncology from Tata Memorial Hospital, Mumbai.

    Dr. Kate has managed both conservative and surgical cancer treatments. She is skilled in complex procedures such as the Whipple surgery. She is a member of several leading oncology societies, including ASCO, ESMO, IASCLC, ISMPO, and IOS. Her research on lung cancer received the only travel award from India at the 2018 World Conference on Lung Cancer.

  • Толығырақ оқу
Туыстық емес донордан алынған жұлың кемігін аллогендік трансплантациялау
$37,500 - $39,000
Уиппл операциясы
$8,000 - $10,000
Ақпарат

Sudarshan Pandit

  • Жаңа
  • 11 жылдар тәжірибе
  • Үндістан, Нашік, HCG Manavata Cancer Centre
Туыстық емес донордан алынған жұлың кемігін аллогендік трансплантациялау
$37,500 - $39,000
Уиппл операциясы
$8,000 - $10,000
Ақпарат

Ahmer Arif Shaikh

  • Жаңа
  • 15 жылдар тәжірибе
  • Үндістан, Нашік, HCG Manavata Cancer Centre
  • Dr. Ahmer Arif Shaikh, MDS (Oral & Maxillofacial Surgery), is a specialist in Surgical Oncology. He has 3 years of experience at HCG Manavata Cancer Centre, Nashik. He focuses on oral cancer treatment, organ preservation, and functional rehabilitation for oral cancer patients.

    Dr. Shaikh has completed a Fellowship in Head & Neck Surgical Oncology. He is skilled in complex maxillofacial and head & neck surgeries. He is also an active researcher with several publications in reputed journals. His work shows a strong commitment to improving cancer care.

  • Толығырақ оқу
Туыстық емес донордан алынған жұлың кемігін аллогендік трансплантациялау
$37,500 - $39,000
Уиппл операциясы
$8,000 - $10,000
Ақпарат

Lalit Banswal

  • Жаңа
  • 15 жылдар тәжірибе
  • Үндістан, Нашік, HCG Manavata Cancer Centre
  • Dr. Lalit Banswal is an experienced oncological surgeon with 10 years in the field. He has performed more than 10,000 major surgeries. He earned his MBBS from MIMER, Pune, and completed his MS at GMC Panaji. He also completed a fellowship in Surgical Oncology at Tata Medical Centre, Kolkata, with a focus on gastrointestinal cancers.

    Dr. Banswal has worked as a Co-principal Investigator in several research projects. He has published his work in both national and international journals. He is known for his patient-friendly and ethical approach. His main expertise is in Minimal Invasive Cancer Surgeries, where he consistently delivers excellent results.

  • Толығырақ оқу
Туыстық емес донордан алынған жұлың кемігін аллогендік трансплантациялау
$37,500 - $39,000
Уиппл операциясы
$8,000 - $10,000
Ақпарат